Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06721299 · ClinicalTrials.gov registry record · Phase 1
Clenbuterol to Target DUX4 in FSHD
A Phase 1 study of Muscular Dystrophy, Facioscapulohumeral, sponsored by Jeffrey Statland.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT06721299: Recruiting Phase 1 study of Muscular Dystrophy, Facioscapulohumeral, sponsored by Jeffrey Statland.
NCT06721299 is a Phase 1 study of Muscular Dystrophy, Facioscapulohumeral that is actively recruiting participants, run by Jeffrey Statland. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06721299, a Phase 1 study of Muscular Dystrophy, Facioscapulohumeral, is actively recruiting participants, sponsored by Jeffrey Statland.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine if Clenbuterol is a therapeutic option for FSHD by determining the safety and tolerability of the medication at three different dose levels.
Primary Outcome
Patient report and medical records will be used to document adverse events and severe adverse events. Adverse events and severe adverse events will be assessed by the investigator and reported as needed for safety.
Conditions Studied
Interventions
- DRUG Clenbuterol
Study Locations (3)
Kansas
- University of Kansas Medical Center - Kansas City
New York
- University of Rochester Medical Center - Rochester
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-06-25 |
| Est. Completion | 2028-07 |
| Phase | Phase 1 |
What NCT06721299 shows while recruiting
NCT06721299 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Muscular Dystrophy, Facioscapulohumeral appearing as the primary indexed condition, and to 1 intervention - of which Clenbuterol is the first listed.
NCT06721299 reports a single indexed study location in Kansas, New York, Washington.
Frequently Asked Questions
What is clinical trial NCT06721299 about?
NCT06721299 is a clinical study titled "Clenbuterol to Target DUX4 in FSHD". The purpose of this study is to determine if Clenbuterol is a therapeutic option for FSHD by determining the safety and tolerability of the medication at three different dose levels.
What is the current status of trial NCT06721299?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-06-25. Estimated completion is 2028-07.
What conditions does trial NCT06721299 study?
This clinical trial studies the following conditions: Muscular Dystrophy, Facioscapulohumeral.
What interventions are being tested in trial NCT06721299?
The interventions under investigation include: Clenbuterol (DRUG).
Who is sponsoring clinical trial NCT06721299?
This trial is sponsored by Jeffrey Statland, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06721299 being conducted?
This trial has 3 study locations across Kansas, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscular Dystrophy, Facioscapulohumeral
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06721299's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI